KRAS and pancreatic neoplasm: In two pancreatic cancer cell lines bearing the KRAS G12D mutation (PANC-1 and Panc 04.03), TH-Z827 conferred anti-proliferative effects with IC50 values of 4.4 and 4.7 μM, respectively (Fig. 5a).